Michael Wilensky
Cardiovascular Disease · Birmingham, ALNPI 1801851142
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $217,030 of the $241,458 with a category attached, or 89.9%. 20 manufacturers reported payments, led by Boston Scientific at 39.2% of the total. Reporting peaked in 2019 at $109,667 and has fallen 99.9% since, to $98 in 2025. Among cardiovascular disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 320 payments — averaging $754.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$95K
- Sanofi-aventis U.S. LLC$36K
- Amgen$33K
- Esperion Therapeutics, Inc.$31K
- Novartis$28K
- Regeneron Healthcare Solutions, Inc.$8K
- plus $11K from 14 others
What the payments were for
- Consulting fees$1,8631%
- Speaking & faculty fees$217,03090%
- Travel & lodging$13,9356%
- Food & beverage$8,6314%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 92 | $94,666 |
| Sanofi-aventis U.S. LLC | 30 | $36,453 |
| Amgen | 37 | $32,584 |
| Esperion Therapeutics, Inc. | 30 | $30,767 |
| Novartis | 64 | $27,791 |
| Regeneron Healthcare Solutions, Inc. | 17 | $8,114 |
| Pfizer | 8 | $6,146 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,390 |
| Abbott | 18 | $842 |
| Abiomed | 1 | $130 |
| Sanofi | 1 | $125 |
| Baxter Healthcare | 1 | $120 |
| Medtronic | 1 | $108 |
| AbbVie(2 entities) | 4 | $67 |
| Johnson & Johnson | 4 | $57 |
| Amarin Pharma, Inc. | 3 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Edwards Lifesciences | 1 | $14 |
| Chiesi USA, Inc. | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN Access System$47,896
- PRALUENT$42,810
- Watchman$41,719
- Repatha$32,359
- NEXLIZET$30,525
- NEXLETOL$30,525
- ENTRESTO$25,792
- ELIQUIS$9,411
- GENERAL - THERAPIES$3,419
- LEQVIO$1,363
- MULTAQ$1,025
- XIENCE SIERRA$221
- GENERAL EP$203
- Impella$130
- Optis Coronary Imaging System$127
- GENERAL - STRUCTURAL HEART$122
- TACHOSIL$120
- Confirm Rx$120
- Claria MRI$108
How this compares
$241,458 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 17 | $83 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
- Christopher DegroatBirmingham$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.